Shields Matthew sold $322K of TEVA

Shields Matthew (EVP, Global Operations) sold 9,989 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $32.19 ($0.32M total) on 2026-06-18.

Original reporting
SEC EDGAR · Shields Matthew
Published Jun 22, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEVA
Neutral
low confidence
Mentioned
$TEVA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVANeutralLow
01

Why it matters

The newest fact is the specific sale size, price, and post-transaction holdings (0 shares), which may slightly influence sentiment but does not change TEVA fundamentals in the text.

02

Market read

Traders may note the insider selling signal, but the disclosure alone is unlikely to be a standalone catalyst.

03

What to watch

No 10b5-1 plan is indicated, but the article also lacks context on total holdings history, tax events, or whether other insiders made offsetting buys.

Relevance 4/10Novelty 4/10Timing: after-hours/filing date (2026-06-22) for an insider sale executed 2026-06-18

Background

This is an SEC Form 4 insider transaction for TEVA, reported by Matthew Shields (EVP, Global Operations).

Company-level read

Ticker impact

$TEVANeutralLow confidence
Context

TEVA disclosed an EVP Global Operations open-market sale of 9,989 shares at $32.1901 on 2026-06-18 via Form 4.

Expected impact

Likely limited near-term impact; any effect would be small and quickly absorbed unless followed by additional disclosures.

Evidence & confidence

The filing is a routine Form 4 open-market sale with no 10b5-1 plan stated and no accompanying operational/financial guidance change.

Market effects

No sector read-across; this is company-specific insider transaction disclosure.

None indicated; TEVA is the only subject with a disclosed transaction.

Minimal; no deal, regulatory action, or operational update is described.

Counterpoint

The sale could be liquidity/portfolio rebalancing rather than a bearish signal, especially since the transaction is labeled open-market and the filing provides no stated reason.

Key entities

  • TEVA PHARMACEUTICAL INDUSTRIES LTD

    Subject of the Form 4 insider transaction disclosure.

  • Shields Matthew

    EVP, Global Operations who sold 9,989 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TEVAMed

Teva Pharmaceutical Industries Ltd (TEVA) Q3 2026 Earnings Call Highlights

Teva Pharmaceutical (TEVA) reported a 2% revenue decline in Q3 2026, driven by a 16% drop in generics revenue. The company discontinued a Phase II study and faces challenges with AUSTEDO revenue due to pricing pressures. CEO Richard Francis and CFO Eli Kalif discussed gross margin expansion, IRA impact, and growth drivers like UZEDY, AJOVY, and WELTRUZA. Teva expects AUSTEDO to reach $2.5B in 2027 and over $3B at peak, despite litigation risks and biosimilar challenges.

$TEVAHighAI 8/10

H.C. Wainwright raises Teva Pharma stock price target to $54

H.C. Wainwright raised Teva's (NYSE:TEVA) price target to $54 from $52, citing strong Q3 results. Revenue was $4.395B (down 2% YoY, up 6% sequentially), and EPS was $0.86 (beating estimates). The company raised its full-year revenue guidance to $16.7B-$17.0B. Austedo, Ajovy, and Uzedy drove higher expectations. BofA Securities also raised its target to $48.

$TEVAMed

Teva’s $420M Samsung Bioepis Deal Includes Biosimilar Banned From US Until 2029 Patent Expires

Teva and Samsung Bioepis agreed to a $420M deal for two biosimilars. Teva gains US rights to RENFLEXIS (infliximab-abda), which can be sold immediately, and ETICOVO (etanercept-ykro), blocked from US sales until 2029 due to patent disputes. The deal includes upfront, launch, and sales milestones. Teva aims to leverage its distribution network to boost RENFLEXIS's market share, while ETICOVO's launch is delayed by legal restrictions.